Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

668P - Matching-adjusted indirect comparison (MAIC) of health-related quality of life (HRQoL) of nivolumab plus cabozantinib (N+C) vs pembrolizumab plus axitinib (P+A) in previously untreated advanced renal cell carcinoma (aRCC)

Date

16 Sep 2021

Session

ePoster Display

Presenters

Camillo Guglielmo Porta

Citation

Annals of Oncology (2021) 32 (suppl_5): S678-S724. 10.1016/annonc/annonc675

Authors

C.G. Porta1, R. Motzer2, F. Ejzykowicz3, S.I. Blum3, M. Hamilton3, J.R. May4, S. Huo3, P. Kral5, C. Ivanescu6, T.K. Choueiri7, D. Cella8

Author affiliations

  • 1 Department Of Internal Medicine, University of Pavia, 27100 - Pavia/IT
  • 2 Department Of Medicine, Memorial Sloan Kettering Cancer Center, New York/US
  • 3 Ww Health Economics And Outcomes Research, Bristol Myers Squibb, Princeton/US
  • 4 Ww Health Economics And Outcomes Research, Bristol Myers Squibb, Uxbridge/GB
  • 5 Patient Centered Solutions, IQVIA, Bratislava/SK
  • 6 Patient Centered Solutions, IQVIA, Amsterdam/NL
  • 7 Department Of Medical Oncology, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Harvard Medical School, 02215 - Boston/US
  • 8 Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago/US
More

Abstract 668P

Background

The landscape for first-line (1L) aRCC is rapidly evolving, with P+A and N+C recommended as standard of care irrespective of risk group by the European Association of Urology and the European Society for Medical Oncology. P+A and N+C have similar modes of action and demonstrated a significant efficacy benefit versus sunitinib (S), although no head-to-head data exist. As aRCC significantly impacts HRQoL, understanding HRQoL benefits of these 2 treatments is of interest to inform clinical decision making.

Methods

An anchored MAIC was conducted using patient-level data from the CheckMate 9ER trial (NCT03141177; N+C vs S) and aggregate published data from the KEYNOTE-426 trial (NCT02853331; P+A vs S). Outcomes included Functional Assessment of Cancer Therapy Kidney Cancer Symptom Index – Disease Related Symptoms (FKSI-DRS) and EQ-5D visual analog scale (EQ VAS) due to limited published HRQoL data from KEYNOTE-426. Hazard ratios for time to first and confirmed deteriorations (TTFD and TTCD, respectively) and baseline to week 30 least squares mean differences in these outcomes were re-estimated for CheckMate 9ER using a weighted population and indirectly compared with those in KEYNOTE-426 via a Bayesian framework.

Results

A total of 651 CheckMate 9ER patients (pts) were matched to 861 KEYNOTE-426 pts using age, region, risk group, sites of metastatic disease, and prior nephrectomy. Results from the MAIC favored N+C versus P+A in all outcomes with statistically significant differences for FKSI-DRS and TTFD in EQ VAS score (Table). Table: 668P

Outcome MAIC results, N+C vs P+A
TTFD, HR (95% CrI)
   EQ-5D VAS 0.73 (0.55–0.96)a
TTCD, HR (95% CrI)
   EQ-5D VAS 0.72 (0.52–1.01)
   FKSI-DRS 0.48 (0.33–0.69)a
Change from baseline at week 30, LSMD (95% CrI)
   EQ-5D VAS 2.55 (–0.88 to 5.98)
   FKSI-DRS 1.85 (0.96–2.74)b

aThe 95% CrI does not contain 1. HR < 1 favors N+C over P+A. bThe 95% CrI does not contain 0. LSMD > 0 favors N+C over P+A. CrI, credible interval; HR, hazard ratio; LSMD, least squares mean difference.

Conclusions

In pts with 1L aRCC, MAIC analyses indicate that compared with P+A, N+C demonstrated a significant improvement in DRS and significantly delayed deterioration in HRQoL. These results, combined with the efficacy and favorable safety profile of N+C, may further inform treatment decisions of clinicians and pts with 1L aRCC.

Clinical trial identification

NCT03141177; NCT02853331.

Editorial acknowledgement

Legal entity responsible for the study

Bristol Myers Squibb.

Funding

Bristol Myers Squibb.

Disclosure

C.G. Porta: Financial Interests, Personal, Invited Speaker, Seminars to Medical Direction Personnel on kidney cancer: Angelini; Financial Interests, Personal, Advisory Board, Consultancy relative to urogenital cancers: AstraZeneca; Financial Interests, Personal, Advisory Board, Advisor relative to development of therapeutics in GU Oncology; speaker at BMS-sponsored meetings; protocol steering committee member: Bristol Myers Squibb; Financial Interests, Personal, Advisory Board, Advisor role relative to the development of Lenvatinib in RCC and HCC; protocol steering committee member: Eisai; Financial Interests, Personal, Invited Speaker, Expert testimony at AIFA; speaker in EUSA-sponsored meetings; advisor relative to the development of Tivozanib; protocol steering committee member: EUSA; Financial Interests, Personal, Invited Speaker, Speaker at GE-sponsored meeting relative to the renal toxicity of CT contrast medium; writing engagement: General Electric; Financial Interests, Personal, Invited Speaker, Speaker at Ipsen-sponsored meeting; advisor relative to the development of Cabozantinib in RCC: Ipsen; Financial Interests, Personal, Invited Speaker, Speaker at Janssen-sponsored meetings: Janssen; Financial Interests, Personal, Advisory Board, Advisor relative to the development of Avelumab in GU malignancies: Merck; Financial Interests, Personal, Advisory Board, Advisor relative to the development of Pembrolizumab and Belzutifan in RCC; Speaker at MSD-sponsored meetings: MSD; Financial Interests, Personal, Invited Speaker, Speaker at Novartis-sponsored meetings: Novartis; Financial Interests, Personal, Expert Testimony, Expert testimony at EMA; consultant for GU Oncology portfolio; Speaker at Pfizer-sponsored meetings: Pfizer; Financial Interests, Personal, Invited Speaker, Member of the Steering Committee of ipi/Nivo EAP in Italy: Bristol Myers Squibb; Financial Interests, Personal, Invited Speaker, Steering Committee Member of CLEAR study: Eisai; Financial Interests, Personal, Invited Speaker, Steering Committee member for Tivozanib Italian EAP: EUSA; Other, Other, Travel support: Roche. R. Motzer: Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Board: Aveo Pharmaceuticals; Financial Interests, Personal, Advisory Board: Eisai; Financial Interests, Personal, Advisory Board: EMD Serono; Financial Interests, Personal, Advisory Board: Exelixis; Financial Interests, Personal, Advisory Board: Genentech/Roche; Financial Interests, Personal, Advisory Board: Incyte; Financial Interests, Personal, Advisory Board: Lilly Oncology; Financial Interests, Personal, Advisory Board: Merck; Financial Interests, Personal, Advisory Board: Novartis; Financial Interests, Personal, Advisory Board: Pfizer; Financial Interests, Institutional, Principal Investigator, Coordinating PI, funding for trial conduct from sponsorto my employer MSKCC: BMS; Financial Interests, Institutional, Principal Investigator, Coordinating PI, funding for trial conduct from sponsorto my employer MSKCC: Eisai; Financial Interests, Institutional, Principal Investigator, Coordinating PI, funding for trial conduct from sponsorto my employer MSKCC: Exelixis; Financial Interests, Institutional, Principal Investigator, Coordinating PI, funding for trial conduct from sponsorto my employer MSKCC: Genentech/Roche; Financial Interests, Institutional, Principal Investigator, Coordinating PI, funding for trial conduct from sponsorto my employer MSKCC: Merck; Financial Interests, Institutional, Principal Investigator, Coordinating PI, funding for trial conduct from sponsorto my employer MSKCC: Pfizer. F. Ejzykowicz: Financial Interests, Personal, Full or part-time Employment: BMS; Financial Interests, Personal, Stocks/Shares: BMS. S.I. Blum: Financial Interests, Personal, Full or part-time Employment: BMS; Financial Interests, Personal, Stocks/Shares: BMS; Financial Interests, Personal, Stocks/Shares: GlaxoSmithKline. M. Hamilton: Financial Interests, Personal, Full or part-time Employment: BMS; Financial Interests, Personal, Stocks/Shares: BMS. J.R. May: Financial Interests, Personal, Full or part-time Employment: BMS; Financial Interests, Personal, Stocks/Shares: BMS. S. Huo: Financial Interests, Personal, Full or part-time Employment: BMS; Financial Interests, Personal, Stocks/Shares: BMS. P. Kral: Financial Interests, Institutional, Full or part-time Employment, Employee of IQVIA who was contracted to perform the analyses for abstract submission: IQVIA. C. Ivanescu: Financial Interests, Institutional, Full or part-time Employment, Employee of IQVIA who was contracted to perform the the analyses: IQVIA. T.K. Choueiri: Financial Interests, Personal, Invited Speaker, Best of ASCO19 talk: Advent Health; Financial Interests, Personal, Other, Consultant on onc drugs: Analysis Group; Financial Interests, Personal, Advisory Board, Advising oncology strategy: Aptitude Health; Financial Interests, Personal, Invited Speaker, ASCO-related event: ASCO-SITC; Financial Interests, Personal, Invited Speaker, CME, ImmunoOncology in RCC: ASiM, CE; Financial Interests, Personal, Advisory Board, Advice on GU/RCC drugs: AstraZeneca; Financial Interests, Personal, Advisory Board, Advice on GU/RCC drugs: BMS; Financial Interests, Personal, Advisory Board, Advice on RCC drug: Calithera; Financial Interests, Personal, Invited Speaker, RCC webinar: Cancernet; Financial Interests, Personal, Invited Speaker, CME, PodCast in RCC ($500.00): Caribou Publishing; Financial Interests, Personal, Advisory Board, Advice on Onc drugs: EMD Serono; Financial Interests, Personal, Advisory Board, Advice on GU/RCC drugs: Exelixis; Financial Interests, Personal, Invited Speaker, CME, Kidney Cancer Association ($1300): France Foundation; Financial Interests, Personal, Advisory Board, Advice on Onc drugs: Infinity; Financial Interests, Personal, Invited Speaker, RCC drug: Ipsen; Financial Interests, Personal, Invited Speaker, Reimbursement ($432.00): Kidney Cancer Association; Financial Interests, Personal, Invited Speaker: Lilly; Financial Interests, Personal, Invited Speaker, Grand Rounds: MDACC; Financial Interests, Personal, Advisory Board, Advice on GU/RCC drugs: Merck; Financial Interests, Personal, Invited Speaker, CME, mjhlifesciences.com (OncLive): MJH Life Sciences; Financial Interests, Personal, Invited Speaker, National Association of Managed Care: NAMC; Financial Interests, Personal, Other, Grant review to Orien Network ($400): ORIEN; Financial Interests, Personal, Invited Speaker, CME, ww2.peerview.com: Peerview; Financial Interests, Personal, Invited Speaker, CME, gotoper.com: PER; Financial Interests, Personal, Advisory Board, Advice on GU/RCC drugs: Pfizer; Financial Interests, Personal, Invited Speaker, CME, researchtopractice.com: ResearchToPractice; Financial Interests, Personal, Invited Speaker, CME, RCC: Springer; Financial Interests, Personal, Advisory Board, Advice on GU Onc drugs: Surface Oncology; Financial Interests, Personal, Invited Speaker, Best of ESMO20 talk ($1000): UAE Society of Onc; Financial Interests, Personal, Invited Speaker, CME, RCC: WebMed; Financial Interests, Personal, Stocks/Shares, 10,000 options, $0.37/share (2020): Pionyr; Financial Interests, Personal, Stocks/Shares, 100,000 options, $0.16/share (2020): Tempest; Financial Interests, Personal, Royalties, For writing and updating chapters in GU Oncology: Up-To_Date; Financial Interests, Institutional, Funding, National co-chair on 3 ongoing trials: Alliance Cooperative Group; Financial Interests, Institutional, Funding, National Chair: AstraZeneca; Financial Interests, Institutional, Funding, National Chair: BMS; Financial Interests, Institutional, Research Grant, for GU oncology translational research through IION program: BMS; Financial Interests, Institutional, Funding, SC member: Eisai; Financial Interests, Institutional, Funding, National co-chair: EMD Serono; Financial Interests, Institutional, Funding, National Chair: Exelixis; Financial Interests, Institutional, Research Grant, for GU oncology translational research: Exelixis; Financial Interests, Institutional, Principal Investigator, Local PI: GSK; Financial Interests, Institutional, Funding, Chair of trial: Lilly; Financial Interests, Institutional, Funding, National Chair: Merck; Financial Interests, Institutional, Funding, National Chair: Peloton; Financial Interests, Institutional, Funding, National co-chair: Pfizer; Financial Interests, Institutional, Principal Investigator, Local PI: Roche; Financial Interests, Institutional, Research Grant, For Health outcomes research: Roche; Financial Interests, Institutional, Principal Investigator, Local PI: Surface Oncology; Financial Interests, Institutional, Funding, National Chair: Takeda; Financial Interests, Institutional, Funding, National Chair: Tracon; Non-Financial Interests, Personal, Leadership Role, Co-Chair of the meeting, 2019, 2020: Kidney Cancer Research Summit of Kidney CAN; Non-Financial Interests, Personal, Principal Investigator, rial Global and National PI with GU Cancers, mostly Kidney Cancer: Multiple Academic and Industry Entities; Non-Financial Interests, Personal, Other, Grants reviewers: AACR; Non-Financial Interests, Personal, Other, Track Leader/Session chair/Speaker/Discussant: ASCO; Non-Financial Interests, Institutional, Other, Access to genomic database: Foundation Med; Non-Financial Interests, Institutional, Other, Access to genomic database: Guardant; Non-Financial Interests, Institutional, Other, Access to genomic database: Invitae; Non-Financial Interests, Personal, Invited Speaker: Medical Communication; Non-Financial Interests, Personal, Other, Reviewer of papers: Various journals (e.g. NEJM, Lancet, JCO); Non-Financial Interests, Personal, Other, Speaker/Discussant: ESMO. D. Cella: Financial Interests, Personal, Other, Consultant: BMS; Financial Interests, Personal, Other, Consultant: Merck; Financial Interests, Personal, Other, Consultant: Novartis; Financial Interests, Personal, Other, Consultant: Pfizer; Financial Interests, Personal, Officer, President: FACIT.org; Financial Interests, Personal, Licensing Fees: FACIT.org; Financial Interests, Institutional, Research Grant: BMS; Financial Interests, Institutional, Research Grant: Merck; Financial Interests, Institutional, Research Grant: Novartis; Financial Interests, Institutional, Research Grant: Pfizer.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.